Biogen Taken To Task Over Spinraza Price In Belgium & Italy
Excessive pricing is once again under the spotlight In Europe. Consumer rights organizations in Belgium and Italy have referred Biogen to the national competition authorities over “exorbitant pricing.”
You may also be interested in...
The firm has stumped up $60m for Ionis’s preclinical antisense asset in spinal muscular atrophy, a potential successor to the slowing Spinraza, which also faces patent expiry in a few years.
A second complaint has been filed, this time in Belgium, over the “excessive” price hike on Leadiant’s CDCA-containing drug for the rare genetic disorder, CTX.
In the latest development in the long-running case pitting Novartis and Roche against the Italian competition authority over a fine imposed in 2014, the Court of Justice of the EU has confirmed that the firms’ arrangement over Avastin and Lucentis could constitute a serious restriction on competition if it involved the dissemination of misleading information. The case now goes back to the Italian court.